Sign Up to like & get
recommendations!
0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz246.089
Abstract: Abstract Background Enadenotucirev (EnAd) is a tumor-selective chimeric Ad11/Ad3 group B oncolytic adenovirus. Following IV dosing of EnAd, viral delivery has been shown in various carcinomas together with CD8+ T-cells. These data provide a rationale…
read more here.
Keywords:
phase;
psioxus;
time employment;
full part ... See more keywords